Profile data is unavailable for this security.
About the company
AddLife AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector. The Company operates through two segments: The LabTech segment is engaged in the sales of laboratory equipment, analytical instruments and reagents, that are used for diagnostics or biomedical research; The MedTech segment offers various medical device equipment, consumables, instruments and devices, primarily to hospitals. The Company operates through number of subsidiaries, such as BergmanLabora AB, BioNordica group, Holm & Halby A/S, Immuno Diagnostic Oy, LabRobot Products AB, Triolab-group, Active Care Sverup AB, Fenno Medical Oy, Mediplast AB, among others.
- Revenue in SEK (TTM)10.42bn
- Net income in SEK309.00m
- Incorporated2014
- Employees2.25k
- LocationAddLife ABBrunkebergstorg 5, Box 3145STOCKHOLM 103 62SwedenSWE
- Phone+46 842003830
- Websitehttps://www.add.life/
Mergers & acquisitions
Acquired company | ALIF B:STO since announced | Transaction value |
---|---|---|
Edge Medical Ltd | 27.05% | 10.33m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CellaVision AB | 747.94m | 152.12m | 4.36bn | 228.00 | 28.69 | 5.21 | 22.73 | 5.84 | 6.38 | 6.38 | 31.36 | 35.16 | 0.7413 | 1.95 | 7.58 | 3,169,233.00 | 15.08 | 14.59 | 17.12 | 17.10 | 68.48 | 68.05 | 20.34 | 19.64 | 2.68 | 40.33 | 0.0267 | 38.49 | 6.78 | 9.39 | 7.99 | 7.25 | 33.00 | -- |
Xvivo Perfusion AB | 854.98m | 137.00m | 6.34bn | 190.00 | 46.60 | 3.03 | 28.30 | 7.42 | 4.32 | 4.32 | 27.03 | 66.43 | 0.3759 | 1.13 | 4.84 | 4,499,900.00 | 6.02 | 3.04 | 6.51 | 3.26 | 75.05 | 73.74 | 16.02 | 10.86 | 3.58 | -- | 0.0138 | 0.00 | 37.63 | 30.08 | 87.52 | 103.46 | 18.21 | -- |
Surgical Science Sweden AB | 946.54m | 141.09m | 7.50bn | 336.00 | 53.16 | 1.68 | 36.49 | 7.92 | 2.77 | 2.77 | 18.55 | 87.73 | 0.1921 | 1.68 | 7.20 | 3,454,507.00 | 2.86 | 3.91 | 3.03 | 4.18 | 68.37 | 68.94 | 14.91 | 21.55 | 3.25 | -- | 0.0004 | 0.00 | 0.1398 | 54.17 | -43.73 | 59.89 | 39.76 | -- |
Revenio Group Oyj | 1.18bn | 213.43m | 8.25bn | 246.00 | 38.61 | 6.57 | 30.25 | 6.97 | 0.7161 | 0.7161 | 3.97 | 4.21 | 0.7604 | 2.99 | 7.06 | 439,489.60 | 13.78 | 14.11 | 15.92 | 17.53 | 71.04 | 70.96 | 18.12 | 20.61 | 2.18 | 24.43 | 0.1018 | 53.12 | 7.19 | 15.91 | -3.20 | 14.64 | 22.93 | 5.92 |
Arjo AB (publ) | 11.40bn | 458.00m | 8.61bn | 7.00k | 20.14 | 1.18 | 5.52 | 0.7551 | 1.68 | 1.68 | 41.84 | 28.78 | 0.7284 | 4.75 | 6.43 | 1,588,736.00 | 2.92 | 3.58 | 4.13 | 5.45 | 43.50 | 43.97 | 4.01 | 5.35 | 0.6853 | 4.62 | 0.3997 | 44.32 | 2.84 | 4.82 | 3.75 | 4.32 | -12.31 | 7.89 |
RaySearch Laboratories AB (publ) | 1.27bn | 223.62m | 9.96bn | 422.00 | 53.38 | 12.94 | 22.85 | 7.87 | 6.52 | 6.52 | 36.93 | 26.89 | 0.6144 | 8.17 | 3.14 | 3,044,546.00 | 10.85 | 2.96 | 16.36 | 4.37 | 91.88 | 90.93 | 17.66 | 5.80 | 1.52 | 217.60 | 0.3277 | 67.90 | 16.62 | 9.96 | 149.49 | 32.19 | 0.5132 | -- |
Biotage AB | 1.96bn | 255.00m | 11.43bn | 622.00 | 44.87 | 2.97 | 26.28 | 5.83 | 3.18 | 3.18 | 24.48 | 48.05 | 0.398 | 1.66 | 7.44 | 2,913,819.00 | 5.18 | 8.47 | 5.86 | 9.93 | 62.62 | 61.62 | 13.00 | 15.07 | 1.56 | 24.71 | 0.0583 | 48.01 | 9.83 | 13.30 | 15.45 | 8.74 | 30.04 | -- |
ChemoMetec A/S | 688.27m | 253.24m | 14.02bn | 184.00 | 55.37 | 15.66 | 49.92 | 20.37 | 9.72 | 9.72 | 26.41 | 34.36 | 0.6943 | 0.7315 | 6.34 | 2,656,324.00 | 25.55 | 27.96 | 30.43 | 35.10 | 80.06 | 79.57 | 36.79 | 35.02 | 2.92 | -- | 0.0128 | 144.08 | -8.22 | 18.37 | -23.72 | 26.64 | 9.97 | -11.81 |
Elekta AB (publ) | 18.02bn | 237.00m | 17.68bn | 4.54k | 77.26 | 2.08 | 11.49 | 0.9812 | 0.6207 | 0.6207 | 47.15 | 23.04 | 0.5967 | 3.73 | 3.05 | 3,972,002.00 | 0.7915 | 3.48 | 1.41 | 6.21 | 37.80 | 38.22 | 1.33 | 6.02 | 0.8634 | 13.35 | 0.461 | 92.20 | -0.5685 | 4.29 | -81.80 | -26.22 | 15.56 | 5.92 |
Vitrolife AB | 3.61bn | 498.00m | 19.83bn | 1.15k | 39.84 | 1.51 | 21.07 | 5.49 | 3.67 | 3.67 | 26.63 | 96.91 | 0.2154 | 3.64 | 5.97 | 3,222,322.00 | 2.97 | -3.38 | 3.08 | -3.52 | 59.32 | 58.06 | 13.80 | -17.40 | 3.08 | 8.14 | 0.1294 | -- | 2.76 | 19.51 | 113.32 | 6.03 | 18.32 | -- |
Embla Medical hf | 8.20bn | 689.99m | 20.84bn | 4.08k | 30.22 | 2.73 | 16.86 | 2.54 | 1.08 | 1.08 | 12.78 | 11.93 | 0.5475 | 2.14 | 6.69 | 1,342,645.00 | 4.64 | 3.77 | 5.48 | 4.42 | 63.19 | 62.22 | 8.47 | 6.60 | 1.10 | 4.85 | 0.3973 | 0.00 | 8.81 | 4.49 | 16.94 | 0.6688 | 4.25 | -- |
AddLife AB | 10.42bn | 309.00m | 21.70bn | 2.25k | 72.61 | 4.38 | 19.29 | 2.08 | 2.54 | 2.54 | 85.49 | 41.99 | 0.8138 | 3.91 | 5.79 | 4,617,908.00 | 2.43 | 4.45 | 3.64 | 7.00 | 37.58 | 37.39 | 2.99 | 5.13 | 0.5252 | 3.01 | 0.483 | 33.59 | 6.21 | 24.21 | 32.63 | 12.38 | 28.28 | 8.45 |
Holder | Shares | % Held |
---|---|---|
SEB Investment Management ABas of 30 May 2025 | 10.84m | 9.20% |
AMF Fonder ABas of 31 Dec 2024 | 10.70m | 9.08% |
ODIN Forvaltning ASas of 30 May 2025 | 7.90m | 6.70% |
Cliens Kapitalf�rvaltning ABas of 31 Dec 2024 | 6.63m | 5.63% |
F�rsta AP-fondenas of 31 Dec 2024 | 6.10m | 5.18% |
Fidelity Management & Research Co. LLCas of 19 Nov 2024 | 6.09m | 5.17% |
The Vanguard Group, Inc.as of 02 Jul 2025 | 4.03m | 3.42% |
Tredje AP-fondenas of 31 Dec 2024 | 3.33m | 2.82% |
ODIN Forvaltning AS (Sweden)as of 30 May 2025 | 3.27m | 2.77% |
Fj�rde AP-fondenas of 30 Jun 2024 | 3.04m | 2.58% |